Monday, June 2 , 2008

OncoLink at ASCO
OncoLink reporters provide in-depth coverage of scientific presentations from the 44th Annual ASCO Meeting.


A phase II randomized, placebo-controlled, double blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP study A phase II randomized, placebo-controlled, double blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP study A phase III randomized study comparing the effects of oxandrolone (Ox) and megastrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer: E4201 A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer: E4201 ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon Cancer-related fatigue interferes with activities of daily living among 753 patiens receiving chemotherapy: A URCC CCOP study Cancer-related fatigue interferes with activities of daily living among 753 patients receiving chemotherapy: A URCC CCOP study CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC) CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC) Effect of paroxetine on depression and insomnia in 547 fatigued cancer patients undergoing chemotherapy Effect of paroxetine on depression and insomnia in 547 fatigued cancer patients undergoing chemotherapy Effects of aerobic exercise training on physical performance during myeloablative therapy Effects of aerobic exercise training on physical performance during myeloablative therapy Electronic self-report assessment for cancer (ESRA-C): Results of a randomized clinical trial Prophylaxis of recurrent chemotherapy-induced oral mucositis: A phase II multicenter, randomized, placebo-controlled trial of recombinant human intestinal trefoil factor (rhITF) Prophylaxis of recurrent chemotherapy-induced oral mucositis: A phase II multicenter, randomized, placebo-controlled trial of recombinant human intestinal trefoil factor (rhITF) Randomized Phase III Trial of Sorafenib Versus Placebo in Asian Patients with Advanced Hepatocellular Carcinoma Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer

Keywords

Click on any of these terms for more related articles

Blogs

Cranberries: Relish the Thought!
by OncoLink Editorial Team
May 27, 2013

In Celebration of Eric Ott
by Bob Riter
August 17, 2015

Related News

Men, young adults, single individuals more likely to use cigarettes along with other tobacco products

Aug 9, 2010

Men, young adults, single individuals more likely to use cigarettes along with other tobacco products


2002 to 2008 Saw Increase in Partial Nephrectomy Use

Feb 20, 2012

For patients with renal masses, use of partial nephrectomy increased from 15.3 to 24.7 percent


Number of Lymph Nodes Tested for Colon CA Up 1988 to 2008

Sep 14, 2011

But no significant increase in lymph node positivity during the same period